Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171
Description
This study is aimed to evaluate the safety, tolerability, and pharmacokinetics (PK), as well as to select an appropriate dosing regimen for the pivotal clinical trial of GST-HG171, an orally bioavailable, potent, and selective 3CL protease inhibitor
